Evidence map›Paper›PMID 39042439›Full record

ArticleJMIR formative research2024

Adding Virtual Reality Mindful Exposure Therapy to a Cancer Center's Tobacco Treatment Offerings: Feasibility and Acceptability Single-Group Pilot Study.

Riley Walton Jackson, Ann Cao-Nasalga, Amy Chieng, Amy Pirkl, Annemarie D Jagielo, Cindy Xu, Emilio Goldenhersch, Nicolas Rosencovich, Cristian Waitman, Judith J Prochaska

Registry-linked trialAbstract read
In one paragraph

Article in JMIR formative research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05220254 (Stanford Tobacco Treatment Services - Virtual Reality Treatment for Smoking Cessation), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05220254 nacompletednot on this map

Stanford Tobacco Treatment Services - Virtual Reality Treatment for Smoking Cessation

TypeinterventionalSponsorStanford UniversityRan2021 to 2022Enrolled20ConditionsSmoking Cessation, MindCotine Virtual Reality Mindful Exposure TherapyArmsMindCotine's VR app
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Riley Walton JacksonDepartment of Medicine, Stanford University, Stanford, CA, United States.ORCID https://orcid.org/0009-0009-9859-1665
Ann Cao-NasalgaHealth Education, Engagement and Promotion, Stanford Health Care, Stanford, CA, United States.ORCID https://orcid.org/0009-0005-1816-8973
Amy ChiengStanford Prevention Research Center, Department of Medicine, Stanford University, Palo Alto, CA, United States.ORCID https://orcid.org/0000-0003-2739-7338
Amy PirklHealth Education, Engagement and Promotion, Stanford Health Care, Stanford, CA, United States.ORCID https://orcid.org/0009-0001-4036-9625
Annemarie D JagieloPGSP-Stanford PsyD Consortium, Palo Alto University, Palo Alto, CA, United States.ORCID https://orcid.org/0009-0003-8893-507X
Cindy XuHealth Education, Engagement and Promotion, Stanford Health Care, Stanford, CA, United States.ORCID https://orcid.org/0000-0002-0286-772X
Emilio GoldenherschLaboratorio de Investigación en Neurociencia y Ciencias Sociales, Universidad de Flores, Buenos Aires, Argentina.ORCID https://orcid.org/0000-0001-9672-7578
Nicolas RosencovichEscuela de Ingeniería Biomédica, Universidad Nacional de Córdoba, Córdoba, Argentina.ORCID https://orcid.org/0000-0003-2100-4070
Cristian WaitmanUniversidad Siglo XXI, Córdoba, Argentina.ORCID https://orcid.org/0000-0001-9996-1140
Judith J ProchaskaStanford Prevention Research Center, Department of Medicine, Stanford University, Palo Alto, CA, United States.ORCID https://orcid.org/0000-0001-7925-326X

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI MICHAEL KENNEY · 2007 to 2026
$71.4M
NCI NIH HHS P30 CA124435
6 · The paper itself

Abstract

backgroundSmoking contributes to 1 in 3 cancer deaths. At the Stanford Cancer Center, tobacco cessation medication management and counseling are provided as a covered benefit. Patients charted as using tobacco are contacted by a tobacco treatment specialist and offered cessation services. As a novel addition, this study examined the acceptability of a virtual reality (VR) mindful exposure therapy app for quitting smoking called MindCotine.

objectiveThe objective of this study was to determine the feasibility and acceptability of offering 6 weeks of MindCotine treatment as a part of Stanford's Tobacco Treatment Services for patients seen for cancer care.

methodsAs part of a single-group pilot study, the MindCotine VR program was offered to English- or Spanish-speaking patients interested in quitting smoking. Given the visual interface, epilepsy was a medical exclusion. Viewed from a smartphone with an attachable VR headset, MindCotine provides a digital environment with audiovisual content guiding mindfulness exercises (eg, breathing techniques, body awareness, and thought recognition), text-based coaching, and cognitive behavioral therapy-based self-reflections for quitting smoking. Interested patients providing informed consent were mailed a MindCotine headset and asked to use the app for 10+ minutes a day. At the end of 6 weeks, participants completed a feedback survey.

resultsOf the 357 patients reached by the tobacco treatment specialist, 62 (17.3%) were ineligible, 190 (53.2%) were not interested in tobacco treatment services, and 78 (21.8%) preferred other tobacco treatment services. Among the 105 eligible and interested in assistance with quitting, 27 (25.7%) were interested in MindCotine, of whom 20 completed the informed consent, 9 used the program, and 8 completed their end-of-treatment survey. Participants using MindCotine completed, on average, 13 (SD 20.2) program activities, 19 (SD 26) journal records, and 11 (SD 12.3) coaching engagements. Of the 9 participants who used MindCotine, 4 (44%) reported some dizziness with app use that resolved and 7 (78%) would recommend MindCotine to a friend. In total, 2 participants quit tobacco (22.2% reporting, 10% overall), 2 others reduced their smoking by 50% or more, and 2 quit for 24 hours and then relapsed.

conclusionsIn a feasibility and acceptability pilot study of a novel VR tobacco treatment app offered to patients at a cancer center, 4 of 9 (44%) reporting and 4 of 20 (20%) overall substantially reduced or quit using tobacco after 6 weeks and most would recommend the app to others. Further testing on a larger sample is warranted.

trial registrationClinicalTrials.gov NCT05220254; https://clinicaltrials.gov/study/NCT05220254.

Indexed as

cancer careexposure therapymobile phonetobacco cessationvirtual reality

Identifiers

PMID39042439
PMCPMC11303906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.